Healthcare / Drug Manufacturers - GeneralXETRA
$922.80
-14.00 (-1.49%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 17%
FCF escenarios
weak_data · normalized FCF $414.0M · quality 28.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
62/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$822.9B
P/E
38.2x
↑EV/EBITDA
27.3x
↑ROE
77.8%
↑Gross Margin
83.0%
↑Debt/Equity
1.60
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+31.7%
FCF CAGR
+9.0%
FCF margin
9.2%
FCF / Net income
0.29x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $65.18B · net income $20.64B · FCF $5.96B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $65.18B | $65.18B | $45.04B | $34.12B | $28.54B |
| Net Income | $20.64B | $20.64B | $10.59B | $5.24B | $6.24B |
| EBITDA | $31.69B | $31.69B | $18.81B | $11.85B | $8.66B |
| EPS | 22.95 | 22.95 | 11.71 | 5.80 | 6.57 |
| Gross Margin | 83.0% | 83.0% | 81.3% | 79.2% | 76.8% |
| Operating Margin | 45.6% | 45.6% | 37.8% | 30.3% | 29.0% |
| Net Margin | 31.7% | 31.7% | 23.5% | 15.4% | 21.9% |
| Balance Sheet | |||||
| Debt/Equity | 1.60 | 1.60 | 2.36 | 2.34 | 1.52 |
| Current Ratio | 1.50 | 1.50 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $5.96B | $5.96B | $414.0M | $-3.15B | $4.60B |
| Returns | |||||
| ROE | 77.8% | 77.8% | 74.2% | 48.6% | 58.6% |
| Valuation | |||||
| P/E | 38.18 | 38.18 | 64.75 | 97.41 | 52.30 |
| EV/EBITDA | 27.30 | 27.30 | 38.06 | 44.95 | 39.35 |
| P/B | 31.27 | 31.27 | 48.03 | 47.38 | 30.67 |
| Growth & Yield | |||||
| Revenue Growth | 44.7% | 44.7% | 32.0% | 19.6% | — |
| EPS Growth | 96.0% | 96.0% | 101.9% | -11.7% | — |
| Dividend Yield | 0.6% | 0.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
52.8%
EPS terminal req.
$81.88
Spread vs growth
43.2%
5Y implied EPS CAGR
34.0%
EPS terminal req.
$99.08
Spread vs growth
62.0%
10Y implied EPS CAGR
21.4%
EPS terminal req.
$159.57
Spread vs growth
74.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+40.1%
Start / end P/E
56.5x → 40.2x
EPS bridge
11.71 → 22.95
Residual
-27.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.